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Abstract
Background: With its elusive pathogenesis, dengue imposes serious healthcare, economic and social burden on endemic
countries. This study describes the clinical and immunological parameters of a dengue cohort in a Malaysian city, the first
according to the WHO 2009 dengue classification.
Methodology and Findings: This longitudinal descriptive study was conducted in two Malaysian hospitals where patients
aged 14 and above with clinical symptoms suggestive of dengue were recruited with informed consent. Among the 504
participants, 9.3% were classified as non-dengue, 12.7% without warning signs, 77.0% with warning signs and 1.0% with
severe dengue based on clinical diagnosis. Of these, 37% were misdiagnosed as non-dengue, highlighting the importance
of both clinical diagnosis and laboratory findings. Thrombocytopenia, prolonged clotting time, liver enzymes, ALT and AST
served as good markers for dengue progression but could not distinguish between patients with and without warning
signs. HLA-A*24 and -B*57 were positively associated with Chinese and Indians patients with warning signs, respectively,
whereas A*03 may be protective in the Malays. HLA-A*33 was also positively associated in patients with warning signs when
compared to those without. Dengue NS1, NS2A, NS4A and NS4B were found to be important T cell epitopes; however with
no apparent difference between with and without warning signs patients. Distinction between the 2 groups of patients was
also not observed in any of the cytokines analyzed; nevertheless, 12 were significantly differentially expressed at the
different phases of illness.
Conclusion: The new dengue classification system has allowed more specific detection of dengue patients, however, none
of the clinical parameters allowed distinction of patients with and without warning signs. While the HLA-A*33 may be
predictive marker for development of warning signs; larger studies will be needed to support this findings.
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Introduction
Malaysia is a multiracial country with an estimated population
of 28 million people [1]. Over the years, the country has achieved
tremendous improvement in its health sector; however, infectious
diseases remain as major causes of high morbidity and mortality
rates. Amongst the communicable diseases, dengue has the highest
incidence rates (167.8/100000 population) in Malaysia [1]. It is
also widespread throughout the tropical and subtropical regions of
the world, with an estimated two-fifth of the world population
being at risk of infection [2].
Previously classified as dengue fever (DF), dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS), currently
according to the WHO dengue classification 2009, dengue is
classified as with or without warning signs and severe dengue [3].
Usually, the initial clinical symptoms of dengue patients will not be
able to differentiate mild dengue from severe cases. As the disease
progresses, patients are classified via their clinical presentation
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over time and also via laboratory confirmation. Generally, a
dengue virus (DENV) infected person may be asymptomatic or
may just develop undifferentiated fever, typically with rashes, body
aches and pains, nausea, vomiting and diarrhea. This patient may
then recover or may further deteriorate and develop warning signs
which include persistent vomiting, abdominal pain and tenderness,
bleeding tendencies, fluid accumulation, hepatomegaly, with
increased hematocrits and decreased platelets. In this critical
phase, if not clinically well-managed, severe plasma leakage,
bleeding and organ impairment may occur and can be fatal.
Currently, patients with warning signs require admission into
healthcare facilities for in-hospital management and care [3].
Since Malaysia is dengue hyperendemic [4], the social and
economic burden as well as the disability-adjusted life years
(DALYs) of the country is on a continuous rise [5]. In 2010,
Malaysia had 46171 cases of reported dengue with 134 deaths,
unreported and misdiagnosed cases unaccounted for.
The complexity in dengue pathogenesis has hampered the
development of vaccines and antiviral drugs. Despite decades of
research efforts, dengue immunopathogenesis has become more
complex as various contradicting and controversial findings are
being uncovered around the world [6]. Antibody enhancement
[7], improper T cell [8,9] and cytokine response [10,11], and host
genetic factors [12] are amongst the postulated immunopatho-
genesis leading to severe dengue.
Here, we report the clinical epidemiology of dengue disease in
patients from Klang Valley, Malaysia from 2 major hospitals in the
region. We assessed the clinical and immunological profiles of
dengue suspected patients in hopes of identifying clinical/
biomarkers to enable early diagnosis of disease with respect to
the WHO 2009 classification.
Methodology
Study Design and Study Population
This longitudinal descriptive study was conducted in the
emergency department and dengue wards of two hospitals situated
in the Klang Valley, Malaysia: Ampang Hospital (Ampang,
Selangor) and Tengku Ampuan Rahimah Hospital (Klang,
Selangor) from June 2010 to April 2011. Study inclusion criteria
included: (i) patients above the age of 18 or if between 14–18 years
of age with parental consent and (ii) with clinical symptoms
suggestive of dengue as described in the WHO 2009 dengue
classification and determined by medical officers. Patients who met
the criteria were recruited with written informed consent was
obtained. For minors written parental consent was obtained on
behalf of the 14–18 year-old group. Ethical clearances were
obtained for all procedures performed from all hospitals and
laboratory involved: University Malaya Medical Center (782.90),
Ampang Hospital (NMRR-10-683-6420), Tengku Ampuan Rahi-
mah (NMRR-10-683-6420) and University of South Florida
(Pro00000425). The study was conducted in keeping with the
Declaration of Helsinki (amended Seoul, Korea 2008) on human
studies.
Clinical Data Collection
A standardized form for clinical data collection was designed
and used throughout the recruitment process. The clinical data
collected for this study include (i) demographics, (ii) co-
morbidities, (iii) hospital laboratory findings (iv) clinical symptoms
(v) blood, liver and kidney profiles at three different phases of
illness and (vi) clinical diagnosis. The classification of dengue
patients was determined by clinicians based on the criteria of the
WHO 2009 dengue classification using clinical diagnosis and also
the hospital laboratory diagnostics. The 2009 dengue classifica-
tion classifies dengue patients into non-dengue (ND), dengue
without warning signs (DwoWS), dengue with warning signs
(DwWS) and severe dengue (SD). Curve fitting was done using
the LOWESS coarse curve to follow the general trends of clinical
parameters in the DwoWS and DwWS patients by the day of
illness (DOI). Statistical analysis was performed to compare the
differences in clinical parameters between patient groups using
the two-tailed Kruskal-Wallis one-way analysis of variances
(ANOVA), followed by Dunn’s multiple comparison test. All
analyses were done via GraphPad Prism 5 for Windows version
5.01.
Blood Collection and Processing
Venous blood was collected from each participant at three
different disease phases: febrile, defervescence and convalescence.
Febrile phase was when the patient presented typical clinical
symptoms of dengue including fever, rash, and body aches.
Defervescence was when patient’s fever had abated and an
increase was noted in capillary permeability or hematocrit with
concurrent decrease in platelets, as well as manifestations of
various signs of severity lasting for 24–48 hours. Lastly the
convalescence phase samples were collected a week after the
defervescence stage; however with certain exceptions in which
patients could not follow up at the appointed time. The blood
collected was separated for serum, plasma as well as PBMC and
were stored at 280uC until further use.
Independent Laboratory Diagnosis of Dengue
As both hospitals conduct only serological diagnostics for
dengue including IgM detection and in some cases, NS1
detection, a separate and independent laboratory diagnostic
testing was performed to confirm the infection status. Serum
samples collected at the 3 different phases from all patients were
subjected to several diagnostics assays. Dengue viral RNA was
detected using one-step SYBR green I real-time RT-qPCR [13].
Dengue specific IgM was detected using an in-house capture IgM
ELISA [14], whereas dengue total antibodies was determined via
haemagglutination inhibition (HI) assay [15]. Dengue NS1 was
detected using the Pan-E Dengue Early ELISA kit (Panbio,
Queensland, Australia). Nevertheless, the findings from this
independent testing were not incorporated with the hospitals’
findings and were not taken into consideration during patient
classification.
DNA Extraction and HLA Typing
Genomic DNA of dengue patients were extracted from whole
blood via the AccuPrep Genomic DNA Extraction kit (Bioneer,
Korea). The extracted DNA was then used in HLA typing via the
Olerup SSP HLA Typing Kits without Taq polymerase. For
determination of HLA-A and HLA-B alleles, the HLA-A Low
Resolution Kits (Lot No. 62G, 04L, 02N) and HLA-B Low
Resolution Kits (Lot No. 20K, 06L, 03N) were applied,
respectively. Interpretations of the HLA alleles were then done
with (i) lot-specific interpretation and specificity tables provided
by the manufacturer and (ii) SCORE program designed based on
‘‘Virtual DNA Analysis’’ (Helmberg SCORE, Olerup SSP). The
association between allele prevalence and dengue infection was
examined using Microsoft Excel and GraphPad Prism 5 for
Windows version 5.01. For each HLA allele, the proportion of
DENV infected patients and control subjects with the allele were
compared, using allele frequency (AF) values with the formula
[16], AF = No of occurrences of a particular allele divided by 2n,
where n is the number of individuals studied. The degree of
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association between HLA alleles and disease state was then
expressed as the odds ratio (OR), which was obtained from
standard contingency table analysis. Groups with higher OR
value suggest increased risk of infection, and vice versa. The P
value was determined by using the two-tailed Fisher’s exact test
with p,0.05 being significant. Due to the small number of
patients in the ND and SD classifications, the clinically diagnosed
ND and DwoWS were grouped into one category, without
warning signs; whereas the DwWS and SD patients were
categorized into with warning signs.
PBMC Isolation and IFN-c Enzyme Linked ImmunoSpot
(ELISpot) Assay
Thirty-six peptides with lengths of 9–10mers were designed
based on Malaysian circulating DENV strains, using two major
histocompatibility complex ligands and peptide motifs databases;
SYFPEITHI [17] or RANKPEP [18] (Table S1). The peptides
were synthesized with more than 90% purity (JPT Peptide
Technologies GmbH, Germany) and were then used in the IFN-c
Elispot assay to determine the T cell responses in dengue patients,
where activated IFN-c will be released and quantitated in a
standard direct ELISA format on nitrocellulose plates [9]. The
spots were read and counted with Zeiss KS Elispot reader (Carl
Zeiss, Germany). The number of spots per well were expressed as
spot forming cells (SFCs) per million PBMCs. A response was
considered significant when the number of SFCs for the patients
was at least twice of the negative control and with a minimum of
50 SFCs per million. As above, the clinically diagnosed ND and
DwoWS were grouped into one category, without warning signs;
whereas the DwWS and SD patients were categorized into with
warning signs. The two-tailed unpaired t-test with Welch’s
correction was used to compare between the groups without
and with warning signs. To compare between different peptide
pools and individual peptides, one-way ANOVA with Kruskal-
Wallis test, followed by Dunn’s Multiple Comparison test was
applied. A probability of less than 0.05 was considered as
significant.
Identification of Cytokines, Chemokines and Growth
Factors
The levels of 16 cytokines (IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6,
IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, IFN-c, MIF, TNF-a, and
TNF-b), 8 chemokines (CCL2, CCL3, CCL4, CCL5, CCL11,
CXCL10, CXCL12 and IL-8), 7 growth factors (FGF-2, G-CSF,
GM-CSF, HGF, IL-7, PDGF and VEGF) and 2 adhesion molecules
(ICAM-1 and VCAM-1) in dengue patients’ sera were evaluated via
BioPlex Pro Assays (Bio-Plex Human Cytokine Assay; Bio-Rad Inc.,
Hercules, CA, USA) [19]. The fluorescent signals were read using
the Bio-Plex 200 System (Bio-Rad Laboratories). Via the Bio-Plex
Manager 6.0 Software, raw data was measured as the relative
fluorescence intensity and then converted to cytokines concentra-
tion based on the standard curve generated (Bio-Rad Laboratories).
Once again, the ND and DWoWS patients were grouped as
‘‘without warning signs’’ and the DwWS and SD patients were
grouped as ‘‘with warning signs’’. The differences in cytokine levels
between the differences groups dengue patients were evaluated
using the Kruskal-Wallis one way analysis of variance (ANOVA),
followed by Dunn’s multiple comparison test. All statistical analyses
performed were done using GraphPad Prism 5 for Windows,
Version 5.01 (San Diego, California, USA).
Results
Characteristics of Study Population- the Klang Valley,
Malaysia Scenario
The study was conducted in two government-based hospitals
located in the Klang Valley; Ampang Hospital and Tengku
Ampuan Rahimah Hospital Klang. A total of 512 patients who fit
the study criteria were recruited at both hospitals and of these, 8
withdrew. The study participants whom had an average age 29.5
years and were mostly male (75.6%) were mainly recruited in the
dengue wards of both hospitals (83.7%). As a multinational
country, the study group when segregated ethnically had 65.5% of
Malays, 13.5% Chinese, 11.7% Indians and 9.3% of other
ethnicities. According to the new WHO classification, 9.3% were
classified as ND, 12.7% as DwoWS, 77.0% as DwWS and 1.0% as
SD (Table 1).
Generally, participants sought medical intervention during the
5th DOI, with the admission average also at 5th DOI. The clinical
symptoms of the dengue suspected patients in general included
vomiting (59.1%), myalgia (56.3%), arthralgia (49.8%), diarrhea
(45.4%), various cerebral symptoms including headaches, and
retro-orbital pain (30.0%) nausea (28.4%), rashes (10.3%) and
petechia (0.8%) (Figure 1). The warning signs in patients included
a concurrent increase in hematocrit with the decrease of platelets,
abdominal pain and tenderness (52.0%), bleeding tendencies
(17.1%), postural giddiness (24.4%), hepatomegaly and tenderness
(22.6%), splenomegaly (0.8%), pleural effusion (1.4%) and ascites
(0.4%). An overwhelming 42.9% of recruited patients were also
diagnosed with acute hepatitis (Table 1).
In both hospitals, the commonly ordered diagnostics assay is the
IgM test, while only 26% of the study cohort was tested for dengue
NS1 (Table 2). From the hospital diagnostics, 44.6% of patients
were IgM positive and 10.3% were NS1 positive. However, as the
clinical diagnosis was based solely on clinical symptoms and
serological data, we applied various other diagnostic assays to
confirm the true status of the recruited cohort before embarking
on further investigations. However, we would like to note that
these laboratory assays were not included in the classification of
dengue patients. From the 4 separate diagnostic assays conducted,
a patient was considered dengue positive when (i) dengue virus
and/or antigen was detected, or (ii) dengue IgM seroconversion
occurred in paired sera, or (iii) dengue total antibodies had a
fourfold rise in titers in paired sera and (iv) a combination of the
above. A presumptive dengue patient, on the other hand, had
either IgM of HI titer of above 1280 but without seroconversion or
fourfold rise, respectively, occurring mainly in patients with single
serum samples. Six patients were not included in the diagnostic
assays, as their blood was in unbefitting conditions upon receipt.
From the laboratory tests, we found 311 patients to be positive for
current dengue infection, 54 with presumptive dengue and 133
negative for all tests carried out (Table 3). Dengue virus was
detected in 49 patients with prevailing serotypes of DENV1
(69.4%) and DENV3 (30.6%). Dengue NS1 was detected in 218
patients, a number much higher than detection of the virus itself.
Out of the 322 patient who had dengue IgM, 15.2% had
seroconversion in their defervescence/convalescence samples. Via
the HI assay, we determined that 221 patients had primary dengue
infections and 140 had presumptive/confirmed secondary infec-
tions, whereas 4 could not be determined.
The rate co-morbidities in this study group were relatively low
(Table 4), where 4.2% of patients had diabetes mellitus, 3.6% had
hypertension, 1.4% had ischemic heart disease, 0.6% had
congestive heart failure and 0.2% had chronic kidney disease.
Patients in this study required an average of 4 (SEM 60.4) days of
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admission, however there were about 2.2% who had been
admitted for more than 10 days. On average, the febrile blood
draw was around day 5 of illness (SEM: 60.3), the defervescence
draw was at day 6 of illness (SEM: 60.3) and the convalescence
draw was at day 11 of illness (SEM: 60.7).
Analyses of the patients’ vital signs (Figure 2A) and kidney
profile (Figure 2E) revealed no significant differences between the
classifications and from the normal range. The mean hematocrit
levels were increased only in the DwoWS patients (53.169.8%),
and these were significantly different from the ND group at febrile
(p = 0.0051) and convalescence (p = 0.0052). The average platelet
counts were low in all four groups during febrile and deferves-
cence. Significant differences were observed between ND group
with DwoWS group during febrile (p = 0.0285) and with DwWS
during defervescence (p,0.0001). Both the prothrombin time (PT)
and activated partial thromboplastin time (APTT) were higher in
both DwoWS and DwWS groups. Generally, the white blood cells,
neutrophils and monocytes levels were in the reference range
(Figure 2C). However, a slight decrease was noted in the
lymphocyte count of DwoWS (1.160.16109/L), DwWS
(1.260.16109/L) and SD (0.6560.36109/L) patients at the
febrile phase. The total protein, bilirubin, albumin, globulin and
alkaline phosphatase levels in all groups were normal (Figure 2D).
However, a significant difference (p = 0.0015) in total bilirubin
levels was noted between DwoWS (13.261.8 mmol/L) and DwWS
(9.460.4 mmol/L) at febrile phase. A considerable dissimilarity
(p = 0.0056) was also noted in the levels of total protein between
DwoWS (66.361.1 g/L) and DwWS (62.360.5 g/L) at deferves-
cence. Alanine transaminase (ALT) was found to be in higher
levels in all four dengue classified groups while aspartate
aminotransferase (AST) was only found to be higher in DwoWS
and DwWS patients throughout the illness.
MHC Class I- HLA-A and -B Alleles Distribution and
Association with Dengue Infection
The adaptive immune system plays an important role in host
defense against viral infections and a major component of this
system is the MHC molecules, responsible for antigen display.
Pathogenic variants of MHC molecules have been hypothesized to
cause severity in dengue [12] and hence, from the laboratory
confirmed/presumptive patients, 227 were selected by their
ethnicities (Malay, Chinese and Indians- excluding those with
mixed parentage) for HLA-A and HLA-B typing. Eighteen HLA-
A and 29 HLA-B alleles were detected in both the control and
diseased groups. In both with and without warning signs groups, 5
HLA-A alleles (A*01, A*02, A*11, A*24 and A*33) and 5 HLA-B
alleles (B*13, B*15, B*18, B*35 and B*40) were detected at
frequencies higher than 5% (Figure 3). Patients without warning
signs also had increased frequencies of while those with warning
signs had increased B*44 and B*58. Four alleles, B*14, B*42, B*47
and B*54 were not detected in the diseased group. Stratification by
ethnicity showed that Malay patients with and without warning
signs had A*02, A*11, A*24, A*3, B*15, B*18, B*35 and B*40 at
higher AF. Meanwhile, A*01 and B*13 was only increased in
Malay without warning signs patients whom also had A*34, B*07
and B*58 at higher AF. In the Chinese patients, A*01 was not
detected at all, while B*15 was detected only in without warning
signs and B*35 in those with warning signs. Several other alleles
were up-regulated in the Chinese patients including B*38, B*46
and B*58. While most alleles were highly expressed in the Indian
groups of patients, A*33, B*13 and B*18 were only increased in
patients with warning signs. Furthermore, alleles B*51, B*57 and
B*58 were also highly expressed in this group of Indian patients. In
this case- control retrospective study, the odds ratio was calculated
in order to find HLA alleles association with dengue disease.
Alleles, A*34 and B*15 were found to have positive associations
with patients without warning signs regardless of ethnicity,
whereas A*03 was negatively associated with this group of patients
Table 1. Demographics on study population based on clinical diagnosis.
ND DwoWS DwWS SD
No. Patients 47 64 388 5
Diagnosed with hepatitisa 3 16 165 2
Recruitment area
Emergency 24 10 46 2
Ward 23 54 342 3
Age (Mean ± SEM) 15–81 (29.162.0) 13–60 (29.961.5) 12–77 (29.560.6) 22–39 (27.562.6)
Sex
Female 13 11 98 1
Male 34 53 290 4
Race
Malay 31 37 259 3
Chinese 3 11 52 2
Indian 8 7 44 0
Others 5 9 33 0
Pregnancy 1 0 2 1
Previous DENV Infectionb 1 2 22 0
ND: Non dengue; DwoWS: Dengue without warning signs; DwWS: Dengue with warning signs; SD: Severe dengue; SEM: Standard error mean;
aDischarged with the respective classification and with hepatitis;
bPrevious known dengue infections to the knowledge of the patient.
doi:10.1371/journal.pone.0092021.t001
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Figure 1. Clinical symptoms of the study population. *indicates the symptoms/manifestations considered as warning signs by the WHO 2009
dengue classification. Detailed clinical symptoms (in percentages) by dengue classification are given in the table.
doi:10.1371/journal.pone.0092021.g001
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(Table 5) when compared to the healthy donors. In those with
warning signs, allele B*15 had a positive association whereas A*03
had a negative association (Table 5). When patients with and
without warning signs were compared, allele A*33 was positively
associated with increased risk of having warning signs and having
allele A*34 could possibly minimize the chances of developing
warning signs (Table 5).
IFN-c T-cell Response in the Dengue Population
Presentation of antigenic peptides by the HLA molecules on
APCs will activate cell-mediated immunity. Improper activation of
these cells, mainly the cytotoxic T lymphocytes, has been
suggested to play a role in dengue severity. Therefore, we sought
to investigate the T cell activation of dengue infected patients via
IFN-c ELISpot. First, the designed peptides were pooled to
evaluate the T cell responses of 156 dengue positive patients from
the study population who were HLA-typed. 78.2% patients were
with warning signs whereas the rest were patients from the dengue
positive ND and DwoWS groups. Patients in the ‘‘without warning
signs’’ group did not exhibit any warning signs or severe
manifestations. A positive response was ascertained for when the
number of SFC per million PBMCs of patients were twice as much
as that of negative control wells, and above the cutoff point
generated from ELISpot data of the healthy donors. Twenty-five
dengue patients displayed positive T cell responses to at least one
of the peptide pools and 84% were patients with warning signs.
Generally, patients had higher magnitude of response in peptide
pools (Pool C, D, E and F) consisting of the non-structural (NS)
proteins (Figure 4A and 4B). It was also observed that patients with
warning signs had larger magnitudes of responses; however no
significant differences were found between patients with and
without any signs in any of the pooled peptides. All 25 pooled
peptide patients responded to at least one individual peptide
(Figure 4C). Generally most patients tested responded to peptides
designed based on the non-structural proteins where peptide 15
(NS1187–195 AVKDERAVH) and peptide 17 (NS2A179–188
PLCLSTTSQK) had the highest number of respondents. This
was followed by peptides 16 (NS1297–306 SLRTTTVSGK), 220
(NS2B59–13 NEGVMAVGL), 229 (NS4B159–167 VVYDAKFEK).
In the non structural region, NS5 had the lowest T cell response
among the patients tested. The response in the structural protein
was much lower, with the capsid region peptides generating the
most responders.
Cytokine Response in the Dengue Population
Cytokines are important immunomodulators and improper T
cell activation can lead to cytokine storms which are believed to
result in endothelial permeability and leakage, a typical feature of
dengue disease progressing into a more severe stage. Many
cytokines have been implied in causing severe dengue manifesta-
tions, and in this study, 42 patients who were HLA-typed with
positive/borderline T cell response and with distinct characteris-
tics such as absence of any warning signs in the ‘‘without warning
signs’’ group and vice versa, were included. Of the 33 cytokines
studied, none showed differential expression between patients with
and without warning signs. However, when compared to the
controls, 12 cytokines were notably differential expressed at the
different phases of illness (Table 6). IL-7 and MIF was significantly
increased in patients with warning signs at all 3 phases of illness.
During febrile and defervescence, the levels of CCL11, IL-8 and
IL-10 was decreased considerably in patients with warning signs
while cytokines CXCL10 and VCAM-1 was highly expressed.
FGF-2 was only significantly decreased during febrile while
ICAM-1 was increased during defervescence in those with
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warning signs. At convalescence, IL-5, IL-13, and IFN-c were
significantly higher in patients with warning signs. Levels of
CXCL10 and VCAM-1 were also extensively increased in patients
without warning signs during defervescence.
Discussion
Selangor Darul Ehsan, is a highly populated state of Malaysia
and has the largest metropolitan area known as the Klang Valley.
Thus far, this state has had the highest dengue incidence rates.
Our study was conducted in 2 major government-based hospitals
located in the Klang Valley situated about 50 km apart. Both the
average age of the study population and the racial segregation of
the study participants reflect the national age and ethnicity profile
[1]. As observed in our study, the high numbers of male dengue
patients have also been reflected in not only the Malaysian
national dengue data but also in several neighboring countries
including Singapore [20]. The most common clinical symptoms in
this cohort would be vomiting, diarrhea, arthralgia and myalgia;
followed by headaches, nausea and rashes typical of dengue
manifestations. The most frequently observed warning signs were
abdominal pain and tenderness, giddiness and mucosal bleeding
tendencies. Although almost half of the patients were diagnosed
with hepatitis, only 22% had hepatomegaly and liver tenderness.
Currently, the most widely used dengue diagnostic assay in
hospitals is the dengue IgM ELISA [21]. Dengue NS1 detection in
Malaysian hospital settings during 2010–2011 was not obligatory,
therefore the lower administration of this particularly useful test in
the hospital. With no pathognomonic clinical features to
distinguish dengue from other febrile illnesses, laboratory diagnosis
is very important. As dengue IgM can remain in the human body
for 3 months [3] and may hinder the effort to detect acute dengue
infections, we opted to perform other diagnostic assays indepen-
dently which included a separate dengue IgM ELISA and NS1
ELISA as well as RT-PCR and HI. Overall, dengue virus RNA
and/or antibodies and/or dengue NS1 antigens were detected in
62.5% of the study population. Another 10.8% of these patients
were presumed to have dengue while the rest (26.7%) were found
to be negative. Of concern was that (i) 37% of the non dengue
classified patients were positive or presumptive for dengue
Table 3. Laboratory diagnostics confirmation of study population.
Laboratory Diagnostics ND DwoWS DwWS SD
Positive 12 37 259 3
IgM with seroconversion 0 1 4 0
NS1 3 2 12 0
HI 0 0 4 0
IgM+NS1 2 13 77 1
IgM+HI 2 7 68 2
IgM+RT-PCR 0 0 1 0
RT-PCR+NS1 1 2 5 0
NS1+HI 0 1 3 0
IgM+RT-PCR+NS1 1 2 15 0
IgM+RT-PCR+HI 0 0 4 0
IgM+NS1+HI 1 4 55 0
RT-PCR+NS1+ HI 0 0 1 0
IgM+NS1+HI+RT-PCR 2 5 10 0
Presumptive 5 6 43 0
IgM ONLY 4 6 35 0
HI .1280 in a single serum 1 0 8 0
Negative 29 21 81 2
ND: Non dengue; DwoWS: Dengue without warning signs; DwWS: Dengue with warning signs; SD: Severe dengue; IgM: Immunoglobulin M; NS1: Non-structural protein
1; HI: Hemagglutination Inhibiton Assay; +: combination.
doi:10.1371/journal.pone.0092021.t003
Table 4. Co-morbidities in the study population.
ND DwoWS DwWS SD
Diabetes mellitus 4 3 14 0
Hypertension 1 3 14 0
Chronic kidney disease 0 0 1 0
Ischemic heast disease 0 1 6 0
Congestive heart failure 0 1 2 0
ND: Non dengue; DwoWS: Dengue without warning signs; DwWS: Dengue with warning signs; SD: Severe dengue.
doi:10.1371/journal.pone.0092021.t004
Clinical Epidemiology of a Malaysian Dengue Cohort
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e92021
infection and (ii) 23.0% who were clinical diagnosed as dengue
were negative for all assays. This entails the importance of
diagnosing dengue with not only clinical symptoms and param-
eters but in combination with suitable diagnostics assays to avoid
misdiagnosis and under-diagnosis. The HI assay revealed that
60.5% of the positive dengue patients had primary infections while
38.4% had secondary infections. In contrast, when inquired about
having had previous dengue infection, only 25 patients were aware
of having had dengue infection in the past. This highlights the fact
that there could be many silent/inapparent dengue infections
continuously occurring in the country [22]; concurring with the
results from a recent study in Malaysia where 9 out 10 adults were
postulated to have been previously exposed to dengue infection
[23].
This study cohort mostly sought medical interventions in major
hospitals at day 5 of illness, however this may be because most
people seek healthcare treatments from primary care clinics first
[24] before being referred to major hospitals in Malaysia.
Generally, we found that most patients were admitted into either
the observation ward and/or dengue ward immediately upon first
consultation. Most patients went into the critical defervescence
phase on day 6 of illness, and were clinically managed by
healthcare professional by constant monitoring of blood (4 draws/
day), liver and kidney (singular draw/day) profiles. A typical
feature of patients with warning signs is the increase of hematocrit
levels with a concurrent decrease in platelet count. Although the
hematocrit levels in this cohort more or less similar to those of the
controls, the average platelet counts were well below the normal
values. This indicates that thrombocytopenia in dengue patients
Figure 2. Clinical profile of study population. Scatter plot of the study population’s (A) vital signs (temperature, systolic, diastolic and pulse
rate); (B) blood profile (hemoglobin, hematocrit, platelet, prothrombin time, activated partial thromboplastin time); (C) white blood cell profile (total
white blood cells, lymphocytes, neutrophils and monocytes); (D) liver profile (total protein, total billirubin, albumin, globulin, alkaline phosphatase,
alanine transaminase, aspartate aminotransferase) and (E) kidney profile (urea, sodium, potassium, chloride and creatinine) over days of illness. The
LOWESS curves follows the general trend of the observed clinical parameter in dengue patients without (blue) and with (red) warning signs. Grey
zone shows the reference range values.
doi:10.1371/journal.pone.0092021.g002
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Figure 3. HLA Allele Frequencies in the Study Population. (A) HLA-A alleles in the total study population; (B) HLA-B alleles in the total study
population.
doi:10.1371/journal.pone.0092021.g003
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remains an excellent marker to monitor disease progression;
however it is unsuitable as early indicator for distinguishing those
whom may develop warning signs [25]. Taken together, the
prolonged clotting time and decrease in platelet counts observed in
the dengue cohort could be due to DENV interacting with
platelets and megakaryocytes via impaired thrombopoiesis or
through peripheral platelet destruction [26] or nitric oxide activity
in platelets [27].
Leucopenia has been reported to be common in dengue patients
especially towards the critical phase; however in our study, the
average of total white blood cell count remained in normal range.
We observed a general dipping trend around day 4 to 8 of illness
indicating leucopenia may have occurred in a number of patients.
The lymphocytes count was lower in all patients except for the ND
group during febrile phase of illness. These counts gradually
increased as they moved into the defervescence phase, most likely
signifying lymphocytosis during this period. Hepatomegaly with/
without tenderness is frequently reported in dengue patients, often
observed with increased liver enzymes [28,29] where this
phenomenon was also noted in our cohort. The liver enzymes
ALT and AST have been indicated to serve as early markers for
manifestation of severe dengue [25], however, once again with the
2009 dengue classification noteworthy differences between pa-
tients with and without warning signs were not found.
The main limitation of this study is the small number of patients
in the ND and SD group which disallowed us to independently
analyze each dengue classification as its own. Hence, clinically ND
classified patients who were found to be dengue positive/
presumptive and did not display any warning signs were included
in group ‘‘without warning signs’’ while the SD patients whom all
displayed warning signs were grouped as ‘‘with warning signs’’ for
host genetic and immunological characterization. The MHC
molecules including HLA alleles are important for the activation of
T lymphocytes immune response [30], and these genetic factors
have been implicated in disease susceptibility [31] including
dengue [32]. A recent study in Malaysia has indicated that indeed
the HLA alleles may play a role in dengue susceptibility and
protection [33]. Looking at the diseased cohort as a whole, A*03 is
portrayed as a candidate allele for dengue protection as
demonstrated in earlier dengue studies [33,34]. HLA-B*15, with
a positive association with dengue infection, was previously found
also to be susceptible in the Cuban population (38), contrarily,
protective in the Venezuelan population [34]. Being one of the
most polymorphic genes, HLA will have substantial differences in
different ethnic groups [35], and since Malaysia is multiracial
country, the study population was segregated ethnically with
surprising results, where A*24 was notably associated with dengue
susceptibility in the Chinese only. Allele A*24 has been previously
associated with dengue susceptibility and severity in dengue
patients from Vietnam [32], Jamaica [36] and Sri Lanka [37]. In
Indian patients with warning signs, allele B*57 was found to be
positively associated with dengue as was previously shown in the
Venezuelan population [34]. HLA-A*03 which could be a
candidate gene for dengue protection was only found to be
associated with Malay dengue group. HLA-A*34 has not been
associated with any infectious disease thus far, however, has
Table 5. HLA association with dengue of the study population.
Without Warning Sign vs. Controls Control- AF (%) Without WS-AF (%) OR 95% CI P value
Total Population
A*03 9.5 2.4 0.239 0.054–1.055 0.044
A*34 1.1 9.8 10.16 2.108–49.00 0.001
B*15 12.6 24.4 2.231 1.152–4.323 0.02
Chinese
A*24 9.4 35.7 5.37 1.352–21.33 0.023
With Warning Sign vs. Controls Control- AF (%) With WS-AF (%) OR 95% CI P value
Total Population
A*03 9.5 2.7 0.264 0.119–0.584 0.001
B*15 12.6 19.6 1.689 1.025–2.781 0.045
Malay
A*03 9.4 1.2 0.121 0.029–0.500 0.003
Chinese
A*24 9.4 24.3 3.101 1.138–8.451 0.037
Indian
B*57 6.5 25 4.833 1.398–16.72 0.016
Without Warning Sign vs. With Warning Signs Without WS- AF (%) With WS-AF (%) OR 95% CI P value
Total Population
A*33 6.1 15.3 2.787 1.080–7.189 0.032
A*34 9.8 3 0.282 0.110–0.725 0.011
Malay
A*34 13 4.5 0.3197 0.118–0.868 0.028
doi:10.1371/journal.pone.0092021.t005
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Figure 4. IFN-c T cell responses in the study population. (A) SFC per million PBMCs of patients with (red) and without (blue) warning signs in
response to pooled peptide. The mean cutoff values after subtraction of healthy control is at 770SFC/million PBMCs. Mean 6 SEM is given for every
peptide pool. (B) Number of responders towards each peptide pool for patients with (red) and without (blue) warning signs is given in percentage.
(C) SFC per million PBMCs of patients in response to individual peptides. The mean cutoff values after subtraction of healthy control is not given as it
varied for every peptide. The mean response for each peptide is indicated in the mean line. Table below graph shows each individual peptide, and
the number of responders towards these peptides.
doi:10.1371/journal.pone.0092021.g004
Table 6. Significant cytokines at different phases of illness when compared to the controls.
Cytokines Controls Febrile Defervescence Convalescence
Inflammatory cytokines
IL-5 2.6360.90 – – DwWS qq (9.3461.07)
IL-10 11.3261.89 DwWS QQ (0.0360.01) DwWS QQ (0.0260.01) DwoWS QQ (0.0160.00)
IL-13 8.4261.90 – – DwWS qq (31.6163.41)
IFN-c 157.20632.98 – – DwWS qq (408.60624.87)
MIF 267.19653.76 DwWS qq (2497.006341.90) DwWS qq (2201.006354.50) DwWS qq (5166.0063444.00)
Chemokines
IL-8 64.28611.27 DwWS QQ (37.0669.47) DwWS QQ (27.2162.14) –
CCL11 184.40616.32 DwWS QQ (126.90629.12) DwWS QQ (101.80613.22) –
CXCL10 1115.006250.50 DwWS qq (172084.00690626.00) DwoWS qq (115716.00687093.00) –
DwWS qq (41443.00610265.00)
Adhesion molecules
ICAM-1 79313.0065389. 00 – DwWS qq (228076.00625693.00) –
VCAM-1 203603.00623245.11 DwWS qq (460438.0639075.0) DwoWS qq(430763.0648866.0) –
DwWS qq(461180.0646475.0)
Growth factors
IL-7 8.5961.93 DwWS qq (130.10614.37) DwWS qq (142.90620.93) DwWS qq (242.20624.80)
FGF-2 114.00628.240 DwWS QQ (45.8364.72) – –
doi:10.1371/journal.pone.0092021.t006
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positively associated with the dengue patients without warning
signs. Further analysis revealed that this allele may be resistant
against development of warning signs and with ethnicity break-
down, only to be associated in the Malay cohort. HLA-A*33, on
the other hand, seems to promote disease severity or at least the
development of warning signs in dengue patients as was shown
before in cohorts of Thais [38] and Vietnamese [39]. Nevertheless,
up scaling the number of dengue-infected individuals and in other
locations would be required to assess the true potential of these
associations in the Malaysian dengue patients.
Viral antigen presentation on host cells by the HLA molecules
will subsequently activate T cells, and the major concern in
dengue, is the presence of memory T cells which appear to be
cross reactive [40] and/or inefficient in clearing virus [41]. In an
endemic country like Malaysia, where most people are exposed to
the virus, the majority of the population will eventually have
memory T cells. Hence, viral peptides were designed based on
major HLA molecules in Malaysians [33] to elucidate IFN-c T cell
response in this study population. Majority of positive responders
with higher magnitudes of responses were patients with warning
signs, indicating that perhaps these people may have more
activated circulating CD8+ T cells [42]. Peptide pool C consisting
of peptides targeting the NS1 and NS2A region had the highest
number of responders indicating these regions may contain
important T cell epitopes. The NS1 protein, believed to be
involved in DENV RNA replication, has been correlated with
dengue severity [43,44], whereas the NS2A region is believed to
necessary for processing of the NS1 protein [45]. Despite the high
number responders to peptides in NS1 and NS2A areas, the
highest magnitude of response seems to be peptides targeting the
NS4A and NS4B regions. These NS proteins of DENV appear to
be involved in the membrane localization of the viral RNA
replication complex [46].
The ability of our patients to evoke cytotoxic T cell responses has
prompted the study on cytokine levels in these patients, because
such immune activation could trigger a cascade of events eventually
causing an impromptu or overdriven cytokine storm [12,47].
Amongst the 33 cytokines levels analyzed in our cohort, none
displayed significant differences between patients with and without
warning signs; however, 12 were notably different from healthy
controls. IL-7, important for B and T cell development, was found
to be highly expressed in patients with warning signs throughout the
disease and this was also observed in a severe dengue cohort from
Brazil [11]. Another cytokine that was increased in patients with
warning signs is the macrophage inhibition factor where it has been
correlated to dengue severity in various other studies [48,49,50].
This cytokine has been postulated to induce and mediate
production of other pro-inflammatory cytokines [50], triggering a
cascade of cytokine leading to vascular permeability seen in dengue
patients. More recently, MIF induction in dengue infection was
proposed to activate and stimulate endothelial cell to increase
ICAM-1 expression [51]. As was observed in our study, ICAM-1
was indeed increased in patients with warning signs during
defervescence, and this adhesion molecule have been indicated in
endothelium damage and activation [52,53]. VCAM-1, the other
adhesion molecule, was also highly expressed in patients with
warning during febrile and defervescence; however, at deferves-
cence, even patients without warning signs had seemed to have an
increase in VCAM expression. VCAM-1 not only mediates
adhesion of monocytes as well as lymphocytes but is also critical
for endothelial cell survival and in the previous study have been
shown to be increased in dengue patients compared to other febrile
illnesses [54]. Three inflammatory cytokines, IL-5, IL-13 and IFN-c
were found to upregulated in patients with warning signs during
convalescence. CXCL10, was increased in patients with warning
signs during febrile and defervescence and in those without warning
signs during defervescence. CXCL10 is a well-known mediator of
inflammatory responses where its gene has been upregulated in
PBMCs of dengue patients [55]. In contrast to other studies that
showed correlation of increased IL-8 and IL-10 with dengue
severity [56,57], we observed both cytokines to be down-regulated
in dengue patients which may be due to low of number of actual
severe dengue patients in this study. CCL11, important in migration
of eosinophils and induction of CCR3-expressing endothelial cell
migration, were found to be decreased in patients with warning
signs during febrile and defervescence. FGF-2 is important for the
establishment of stable vascular networks, in combination with
PDGF and VEGF [58]. With low levels of this growth factor in
patients with warning signs during the febrile phase of illness,
chances of vascular permeability has increased and may have led to
plasma leakage and hemorrhage observed in these patients.
The new dengue classification system has eased up diagnosis of
dengue disease especially in the clinical settings [59] compared to
the previous classification. However, from our findings, long term
clinical markers for DF and DHF, such as thrombocytopenia and
liver enzymes levels could not discriminate between patients with
and without warning signs. We were also not able to determine
any other clinical parameters that could discriminate between
these two groups. The main shortcoming of this study would be
the low number of severe dengue cases that were available and this
has hindered the ability to identify markers of dengue severity. The
observed association of HLA alleles with dengue could possibly
provide a likely model for predicting the risk factors of acquiring
dengue in the Malaysian population while T cell response study
reiterates NS2A, NS4A and NS4B as well as highlights NS1 as
probable immunodominant sites. Finally, despite not finding any
cytokines that could discern with and without warning signs,
various cytokine trends in the Malaysian cohort had been
documented and warrants further investigations.
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